Acute lymphoblastic leukaemia (Q56722375)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

Acute lymphoblastic leukaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

Ching-Hon Pui

0 references

Les Robison

series ordinal

object named as

Leslie L Robison

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

A Thomas Look

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Ching-Hon Pui

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

English

0 references

publication date

1 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

9617

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

1030-1043

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

Treatment of acute lymphoblastic leukemia

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

The changing scene of adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Moving towards individualized medicine with pharmacogenomics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Birth weight as a risk factor for childhood leukemia: a meta-analysis of 18 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

A pooled analysis of magnetic fields and childhood leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Infections and immune factors in cancer: the role of epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Infection, immune responses and the aetiology of childhood leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Prenatal origin of acute lymphoblastic leukaemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Chromosome translocations and covert leukemic clones are generated during normal fetal development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Origins of chromosome translocations in childhood leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Topoisomerase II inhibitor-related acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Childhood acute lymphoblastic leukaemia--current status and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Molecular genetics of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Cancer stem cells: lessons from leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

MicroRNA expression profiles classify human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Imatinib as a paradigm of targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in c-myc transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Cancer modeling in the modern era: progress and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Zebrafish as a cancer model system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Myc-induced T cell leukemia in transgenic zebrafish

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

1 reference

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Ancestry and pharmacogenetics of antileukemic drug toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Thiopurine methyltransferase in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

High incidence of secondary brain tumours after radiotherapy and antimetabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Management of acute lymphoblastic leukemia in older patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Obesity and outcome in pediatric acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Intensification of Therapy for Children With Lower-Risk Acute Lymphoblastic Leukemia: Long-Term Follow-Up of Patients Treated on Children’s Cancer Group Trial 1881

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic l

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

New therapeutic strategies for the treatment of acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

1 reference

7 January 2021

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960457-2

7 January 2021

10.1016/S0140-6736(08)60457-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18358930%20AND%20SRC:MED&resulttype=core&format=json